Patients were stratified according to dysplasia grade (high versus low) and the length of Barrett esophagus (<4 cm versus 4–8 cm). Regardless of dysplasia grade, radiofrequency ablation was ...

Patients with Barrett's esophagus (dysplasia or early cancer) should be treated and monitored by expert endoscopists and ...

The global market for barrett’s esophagus with dysplasia treatment is poised for significant growth, with a projected ...

Barrett's esophagus is a premalignant condition that predisposes to the development of esophageal adenocarcinoma. The carcinogenetic process of Barrett's mucosa progresses through increasing ...

Z-line=level of mucosal squamo-columnar junction; EGJ=esophagogastric junction; BE= Barrett's esophagus; HGD=high-grade dysplasia; EGD=esophagogastroduodeoscopy. * In selected patients such as the ...

The authors conclude that regression of Barrett's esophagus is more extensive in patients who undergo APC rather than a surveillance protocol. Although high-grade dysplasia was observed only in ...

Castle Biosciences has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher ...

The TissueCypher Barrett’s Esophagus test is Castle’s precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone ...